The search for the means to understand and control the emergence and spread of antimicrobial resistance has become a public health priority. Project ICARE (Intensive Care Antimicrobial Resistance Epidemiology) has established laboratory-based surveillance for antimicrobial resistance and antimicrobial use at a subset of hospitals participating in the National Nosocomial Infection Surveillance system. These data illustrate that for most antimicrobial-resistant organisms studied, rates of resistance were highest in the intensive care unit (ICU) areas and lowest in the outpatient areas. A notable exception was ciprofloxacin-or ofloxacin-resistant Pseudomonas aeruginosa, for which resistance rates were highest in the outpatient areas. For most of the antimicrobial agents associated with this resistance, the rate of use was highest in the ICU areas, in parallel to the pattern seen for resistance. These comparative data on use and resistance among similar areas (i.e., ICU or other inpatient areas) can be used as a benchmark by participating hospitals to focus their efforts at addressing antimicrobial resistance.
Antimicrobial-resistant pathogens pose an enormous challenge for clinicians, infection-control personnel, and hospital administrators. These pathogens have become a prevalent cause of hospital-acquired infections, particularly in patients in intensive care units (ICUs) [1, 2] . However, reports demonstrate that these antimicrobial-resistant pathogens have spread beyond the walls of the traditional acute-care hospital [3] [4] [5] [6] . These reports heighten the need to extend surveillance for antimicrobial resistance to include areas outside of traditional settings.
As antimicrobial use generally precedes the emergence of antimicrobial resistance, preventing the emergence and spread of antimicrobial-resistant pathogens clearly requires optimizing antimicrobial use. A workshop sponsored by the Centers for Disease Control and Prevention (CDC) and the National Foundation for Infectious Diseases made recommendations that hospitals should monitor antimicrobial use in an attempt to reduce the emergence and spread of antimicrobial-resistant pathogens [7] . Such monitoring also can aid the infectioncontrol community in determining how to focus their efforts in reducing the emergence and spread of antimicrobial-resistant pathogens. To create a monitoring tool to use in such efforts, CDC's Hospital Infections Program, in cooperation with the Rollins School of Public Health at Emory University, began Project ICARE (Intensive Care Antimicrobial Resistance Epidemiology) at a subset of hospitals participating in the National Nosocomial Infections Surveillance (NNIS) system at CDC.
Project ICARE provides data on the prevalence of antimicrobial resistance and antimicrobial use in U.S. hospital settings. Data from the eight hospitals participating in phase 1 of this project suggested that most antimicrobial resistance was focused in the ICUs of the hospitals [1, 8] . Here we present data from 41 hospitals participating in phase 2 of Project ICARE. In addition to the data collected, clinical isolates were collected from each hospital to verify reported resistance.
Methods
Participating hospitals. Hospitals that participated in the ICU component of NNIS were eligible to participate in phase 2 of Project ICARE. The surveillance methodology of the NNIS system has been described previously [9] . Hospitals were asked to report at least 12 months of data, beginning in January 1996. All participating hospitals were required to sub-mit data from one or more ICUs to the ICU component of NNIS. For ICARE, hospitals reported additional microbiology and pharmacy data to CDC. These data were aggregated for each month and stratified by hospital area. Hospital areas included each ICU separately (i.e., units that provide intensive observation, diagnosis, and therapeutic procedures for critically ill patients), non-ICU inpatient areas (i.e., areas where the patient stays at least one night in the hospital excluding ICUs), and outpatient areas (i.e., units that perform same-day surgery, simple diagnostic procedures, or therapy, such as chemotherapy, hemodialysis, cardiac catheterization, urgent care, or emergency units).
Microbiology data. Microbiology data included antimicrobial susceptibility test results for all nonduplicate clinical isolates processed by the laboratory during each study month. A duplicate isolate was defined as an isolate of the same species of bacteria with the same antimicrobial susceptibility pattern in the same patient, whatever the site of isolation, during each month. To accommodate differences in susceptibility testing panels among hospitals, reporting of resistance was requested for one or more of a group of related antimicrobials.
Susceptible, intermediate, and resistant isolates of selected organisms were stratified by location in the hospital where the organism was acquired (each ICU ward, inpatient non-ICU units combined, and outpatient areas) for each month, for 12 sentinel antimicrobial-resistant organisms. These included methicillinresistant coagulase-negative staphylococci; methicillin-resistant Staphylococcus aureus; vancomycin-resistant enterococci; penicillin-resistant Streptococcus pneumoniae; ciprofloxacinor ofloxacin-resistant Escherichia coli; E. coli resistant to ceftazidime, cefotaxime, or ceftriaxone; Klebsiella pneumoniae resistant to these third-generation cephalosporins; Enterobacter species resistant to these third-generation cephalosporins; piperacillin-resistant Pseudomonas aeruginosa; ceftazidimeresistant P. aeruginosa; ciprofloxacin-or ofloxacin-resistant P. aeruginosa; and imipenem-resistant P. aeruginosa. All isolates fitting the selected organism-antimicrobial combinations, whether responsible for hospital-or community-acquired infection or for colonization, were reported to Project ICARE by participating hospitals. Hospitals used interpretive standards from the National Committee for Clinical Laboratory Standards (NCCLS) for MIC or zone diameter testing standards to report numbers of susceptible, intermediate, or resistant organisms [10 -12] .
Microbiology isolates. Each ICARE hospital's microbiology laboratory collected up to 20 nonduplicate clinical isolates of select organisms for validation testing at the Project ICARE laboratory at CDC. Only isolates having MICs or zone sizes classified as intermediate or resistant to a specific antimicrobial agent were sent for validation. Each organism sent was accompanied by a completed report form and antibiogram indicating susceptibility test method and hospital-derived resistance pattern. The results of this validation testing provided a sense of the accuracy of each laboratory's methods of susceptibility testing in identifying organisms as resistant.
The following organisms were collected for validity testing: methicillin-resistant S. aureus; vancomycin-resistant enterococci; ceftazidime-, cefotaxime-, or ceftriaxone-resistant K. pneumoniae; ciprofloxacin-or ofloxacin-resistant Enterobacteriaceae; imipenem-resistant Enterobacteriaceae; ciprofloxacin-or ofloxacin-resistant P. aeruginosa; and imipenem-resistant P. aeruginosa. Broth microdilution susceptibility testing was done for these isolates according to NCCLS methods by means of in house-prepared plates [10] .
For the isolates tested for validation, each hospital-derived MIC or disk diffusion zone size was compared with results from broth microdilution testing by use of NCCLS break point interpretations. Organisms defined as causing major errors were those categorized by the hospital as resistant and found to be susceptible by validity testing. Organisms defined as causing minor errors were classified as intermediate by validity testing and as susceptible or resistant by the hospital or classified as intermediate by the hospital and as susceptible or resistant by validity testing.
Pharmacy data. The pharmacy data included in-hospital use of selected oral and parenteral antimicrobial agents in grams. For purpose of analysis, grams of antimicrobials were converted into number of defined daily doses used each month in each hospital area. A defined daily dose is the typical number of grams of an antimicrobial used per day for a typical adult (table 1) [13] . Antimicrobial use was stratified by route of administration and hospital area (i.e., each ICU and inpatient non-ICU areas combined). Because outpatient antimicrobial use could not be estimated reliably from hospital pharmacy records, we did not collect data about outpatient antimicrobial use. Finally, antimicrobials with similar spectrums or clinical indications were grouped (table 1) .
Statistical analyses. The resistance rate of each antimicrobialresistant organism was evaluated in two ways. First, to provide feedback of data to the individual hospitals, the individual resistance rates were calculated at each institution, by hospital area (i.e., individually for each ICU, combined for all non-ICU inpatient areas and for all outpatient areas). Data from each of the hospitals areas were pooled over the entire study period. To calculate a single rate for each hospital area, we divided the number of resistant isolates by the total number of isolates for which susceptibility testing had been done. Resistance rates were calculated for a particular hospital area only if 10 isolates were tested for susceptibility. Second, to compare rates between hospital areas (i.e., all ICUs combined, non-ICU inpatient areas, outpatient areas), a pooled mean resistance rate for each combination of antimicrobial-resistant organisms was calculated by pooling the data from all ICARE hospitals. This rate was the sum of all resistant organisms, divided by the sum of all organisms tested for susceptibility, by hospital area, among all ICARE hospitals.
To control for the population at risk for receiving these drugs, we expressed use as a usage density rate: number of defined daily doses per 1,000 patient-days. Use of antimicrobial agents was determined at each hospital, by hospital area. The pooled number of grams of each antimicrobial agent used, by hospital area, was divided by the number of grams per defined daily dose for the specific antimicrobial agent, then divided by the pooled number of patient-days in the corresponding hospital area, and multiplied by 1,000 to derive the number of defined daily doses per 1,000 patient-days. Pediatric ICUs were excluded from the analysis of antimicrobial use, since the defined daily dose of most antimicrobials studied is less well defined in the pediatric population and commonly depends on weight or age.
Comparisons of proportions (i.e., pooled mean resistance rates of all ICARE hospitals) between hospital areas were done by use of the 2 test. Comparisons of the median rates of antimicrobial use between hospital areas (i.e., ICUs vs. non-ICU inpatient areas) were done by use of the Wilcoxon rank sum test.
Results
Participating hospitals. Phase 2 hospitals were located in 18 states and the District of Columbia: 15 (37%) of these were . Among isolates of Enterobacteriaceae, the proportion of major errors was 67% for Vitek users and 81% for MicroScan users, whereas the proportion among isolates of P. aeruginosa was 22% for Vitek users and 17% for MicroScan users [14] .
Resistance rates. For most of the organisms studied, the percentage of resistant isolates reported from monthly data collection decreased in a stepwise manner by area of the hospital ( figure 1) . The highest resistance rates occurred among isolates from ICU patients, followed in decreasing order by rates among isolates from non-ICU inpatients and rates among isolates from outpatients. These organisms included methicillin-resistant coagulase-negative staphylococci, methicillin-resistant S. aureus, vancomycin-resistant enterococci, piperacillin-resistant P. aeruginosa, ceftazidime-resistant P. aeruginosa, and ceftazidime-, cefotaxime-, or ceftriaxone-resistant Enterobacter species. All of these stepwise decreases were statistically significant except for vancomycin-resistant enterococci, for which the difference bordered on statistical significance (table 3) . However, a second pattern was seen for K. pneumoniae and E. coli resistant to ceftazidime, cefotaxime, or ceftriaxone and for ofloxacin-or ciprofloxacin-resistant E. coli. The pooled mean resistance rates were similar between the adult ICU areas combined and the non-ICU inpatient areas combined (figure 2), even though the resistance rates were still significantly higher for all inpatient areas combined than for outpatient areas (table 3) .
In contrast, for penicillin-resistant S. pneumoniae, the rate of resistance was similar in all hospital areas (i.e., ICU, non-ICU inpatient, outpatient), while the rate of ciprofloxacin-or ofloxacin-resistant P. aeruginosa was significantly higher in outpatient areas than inpatient areas (table 3) .
The rates of antimicrobial-resistant organisms among patients from pediatric ICUs was not significantly different from the rates in adult ICUs (data not shown), with some notable exceptions. Penicillin-resistant pneumococci were more likely isolated from patients in pediatric ICUs than adult ICUs (pediatric, 15 [20 Pharmacy data. The median rate of antimicrobial use was significantly higher in adult ICU areas than in non-ICU areas combined for third-generation cephalosporins combined, ceftazidime alone, intravenous vancomycin, anti-pseudomonal penicillins, intravenous fluoroquinolones, or imipenem (figure 3). However, there was no significant difference in use between ICU and non-ICU areas for the antistaphylococcal penicillins (i.e., methicillin group), first-generation cephalosporins, second-generation cephalosporins, or aztreonam (figure 3). In antimicrobial agents used at significantly higher rates among ICU patients than among non-ICU patients; group 2: agents for which use is similar regardless of hospital location (P Ͻ .05); group 3: agents for which use is significantly lower among ICU patients than among non-ICU patients (P Ͻ .05). contrast, significantly lower rates of use were reported in the adult ICU areas for trimethoprim-sulfamethoxazole, oral vancomycin, or oral fluoroquinolones. However, if oral and parenteral fluoroquinolone uses were combined, rates of usage were similar between ICU and non-ICU areas. Except for parenteral fluoroquinolones, for each of the antimicrobial groups with higher use in ICU areas, there was a correspondingly higher rate of the respective resistant organisms among isolates from ICU patients compared with non-ICU inpatients (figure 4).
Discussion
Our data illustrate that for many common nosocomial organisms, resistance tends to be focused in the intensive care unit setting. Similarly, for many antimicrobials, the rate of use is higher in the ICU areas than non-ICU areas. This higher rate of use parallels the higher rates of resistance observed in the ICU areas for third-generation cephalosporins and Enterobacter species, vancomycin and enterococci, and antipseudomonal penicillins or third-generation cephalosporins and P. aeruginosa ( figure 4) . In other instances, rates of use were similar throughout the hospital, but resistance remained high in ICUs; for example, use of the methicillin group of agents was similar in all hospital areas, but rates for methicillin-resistant S. aureus or methicillin-resistant coagulase-negative staphylococci were higher in ICUs. This suggests that other factors, such as use of other drugs or cross-transmission, play an important role in propagation of these organisms. Further studies to correlate resistance and antimicrobial use among ICUs or hospitals are under way.
A notable exception to the pattern described above was the higher prevalence of ofloxacin-or ciprofloxacin-resistant P. aeruginosa in outpatient areas (20%) than in the non-ICU areas or ICU areas (ϳ17%). These data suggest that ofloxacinor ciprofloxacin-resistant strains of P. aeruginosa now may be present more frequently among patients in settings such as emergency wards and urgent care and outpatient clinics, all of which were included in the outpatient areas of ICARE hospitals. Community-acquired infection due to P. aeruginosa resistant to multiple antimicrobials has previously been associated with cystic fibrosis [15] and other underlying illness, such as infection with HIV [16] . The relationship of our findings to infections among patients in these types of outpatient settings is not clear.
We evaluated in detail how these fluoroquinolones were used in each hospital area. Although intravenous fluoroquinolone use was similar in the ICU and non-ICU inpatient areas, the oral fluoroquinolones were used at a significantly higher rate in the non-ICU inpatient areas than in the ICU areas. We suspect that exposure to oral fluoroquinolones may be high outside the hospital as well, as they are commonly used for many community-acquired infections.
These data also illustrate three difficulties in reporting accurate data from multicenter laboratory-based antimicrobial resistance surveillance systems: uncertain clinical relevance, assuring validity of results, and generalizability of the data. First, to minimize the burden of data collection, we requested all laboratory susceptibility data, not just susceptibility data from patients with nosocomial infections. The latter type of data is collected by hospital personnel performing active surveillance for nosocomial infections, such as is reported to the Surveillance and Control of Pathogens of Epidemiologic Importance (SCOPE) Project [17] or to the non-ICARE components of the NNIS [9] system. Furthermore, Project ICARE received data for all isolates, not just sterile site or respiratory isolates. Consequently, the number of isolates reported from the ICUs in Project ICARE is approximately three-fold greater than that reported from the same ICUs over the same time period to the ICU component of NNIS (i.e., an infection-based surveillance system) [18] . This laboratory-based reporting of all isolates parallels the type of reports many hospital microbiology laboratories generate to track cumulative antimicrobial susceptibility data. Although this type of reporting minimizes the burden of data collection, the clinical relevance of the isolates reported to a laboratory-based system is unclear (i.e., the exact nature of any infection associated with the isolate is uncertain). However, despite the ambiguity of the "infection" status of these isolates, they define the burden of bacteria in the ICU, which in turn relates to the risk of cross-transmission.
Second, there should be a mechanism to validate the results of susceptibility testing to some degree. We requested up to 20 isolates with specific resistance profiles and retested them as described to provide a measure of the validity of the data. We observed that misclassification of imipenem-susceptible strains of Enterobacteriaceae and P. aeruginosa as resistant occurred among Project ICARE hospitals [14] . We suspect that this is occurring in many U.S. hospitals [19] . Imipenem degrades easily. Hospital laboratories should monitor the storage conditions of susceptibility panels, cards, and disks carefully and check quality control results frequently. This experience illus- trates that attempts to aggregate cumulative susceptibility data from several institutions should include validation of the accuracy of laboratory testing techniques. In phase 3 of Project ICARE, we have added a proficiency testing program for the participating laboratories at the time of enrollment as an additional step to improve data quality.
Although this project assessed antimicrobial use for a wide range of antimicrobial agents in a large number of hospitals, these data are not from a representative sample of U.S. hospitals. The hospitals participating in Project ICARE are similar to the other hospitals reporting data to the NNIS system but underrepresent smaller hospitals and certain geographic regions [20] . However, because use varied so significantly between the hospital areas, we believe that reporting of antimicrobial use must be stratified by hospital area to make valid comparisons between hospitals. Further studies are ongoing to determine the importance of specific ICU type as well as regional variations in patterns of antimicrobial use. Furthermore, from these data we cannot assess the relative contribution of specialized patient populations, such as hemodialysis, hematology, or organ transplant patients, to patterns of interpreting antimicrobial use and resistance. In these data, these specialized patient populations are included in the non-ICU inpatient areas. These types of patients may have very atypical dosing patterns of antimicrobials, and assessment of the defined daily dose may not be the best method to characterize antimicrobial use in such specialized patient populations. To address this limitation, data for these specialized patients are currently being collected in phase 3 of Project ICARE.
Project ICARE hospitals have used these data in a quality improvement process by focusing efforts in those areas where reported use is in excess of that in other ICARE hospitals. Routine surveillance of antimicrobial use, such as that described here, can aid hospitals in targeting infection-control efforts. However, further studies are needed to determine the most accurate way of comparing usage data among institutions for quality improvement purposes and to study the impact of antimicrobial control practices on rates of antimicrobial resistance in the health care setting.
Surveillance of antimicrobial resistance among organisms causing hospital-acquired infections is difficult because of the paucity of appropriate data concerning several parameters that are relevant for the study of antimicrobial resistance. These include the case-mix of the patient population, validation of microbiology results, severity of illness, and accurate antimicrobial usage data. In addition, emergence and spread of these organisms do not occur just within the walls of the acute-care hospital. In the era of managed care, extended-care settings and the outpatient setting have become associated with such resistance. Thus, a surveillance system for antimicrobial resistance among organisms causing hospital-acquired infection needs to address these concerns at both the local and national levels (i.e., a multicenter surveillance system is needed). Phase 2 data from Project ICARE underscore the importance of obtaining accurate data about antimicrobial usage and of validating microbiology results. In addition, they suggest that monitoring antimicrobial use in hospitals should help hospitals distinguish problem areas where antimicrobial use appears to be a primary factor contributing to antimicrobial resistance from other areas where factors such as cross-transmission may need increased attention. With information on use and resistance, the infectious disease community will be one step closer to winning the battle against the emergence and spread of antimicrobialresistant organisms in the health care setting.
